C E Smiley1, J T McGonigal2, T Valvano2, R J Newsom2, N Otero3, J T Gass2. 1. Department of Neuroscience, Medical University of South Carolina, Basic Science Building, 173 Ashley Avenue, Room 403, Charleston, SC, 29425, USA. petyak@musc.edu. 2. Department of Neuroscience, Medical University of South Carolina, Basic Science Building, 173 Ashley Avenue, Room 403, Charleston, SC, 29425, USA. 3. Department of Behavioral Sciences, University of Arkansas - Fort Smith, 5210 Grand Ave, Fort Smith, AR, 72904, USA.
Abstract
RATIONALE AND OBJECTIVES: Alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) often occur comorbidly. While the incidence of these disorders is increasing, there is little investigation into the interacting neural mechanisms between these disorders. These studies aim to identify cognitive deficits that occur as a consequence of fear and ethanol exposure, implement a novel pharmaceutical intervention, and determine relevant underlying neurocircuitry. Additionally, due to clinical sex differences in PTSD prevalence and alcohol abuse, these studies examine the nature of this relationship in rodent models. METHODS: Animals were exposed to a model of PTSD+AUD using auditory fear conditioning followed by chronic intermittent ethanol exposure (CIE). Then, rats received extinction training consisting of multiple conditioned stimulus presentations in absence of the shock. Extinction recall and context-induced freezing were measured in subsequent tests. CDPPB, a metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulator, was used to treat these deficits, and region-specific effects were determined using microinjections. RESULTS: These studies determined that CIE exposure led to deficits in fear extinction learning and heightened context-induced freezing while sex differences emerged in fear conditioning and extinction cue recall tests. Furthermore, using CDPPB, these studies found that enhancement of infralimbic (IfL) mGlu5 activity was able to recover CIE-induced deficits in both males and females. CONCLUSIONS: These studies show that CIE induces deficits in fear-related behaviors and that enhancement of IfL glutamatergic activity can facilitate learning during extinction. Additionally, we identify novel pharmacological targets for the treatment of individuals who suffer from PTSD and AUD.
RATIONALE AND OBJECTIVES:Alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) often occur comorbidly. While the incidence of these disorders is increasing, there is little investigation into the interacting neural mechanisms between these disorders. These studies aim to identify cognitive deficits that occur as a consequence of fear and ethanol exposure, implement a novel pharmaceutical intervention, and determine relevant underlying neurocircuitry. Additionally, due to clinical sex differences in PTSD prevalence and alcohol abuse, these studies examine the nature of this relationship in rodent models. METHODS: Animals were exposed to a model of PTSD+AUD using auditory fear conditioning followed by chronic intermittent ethanol exposure (CIE). Then, rats received extinction training consisting of multiple conditioned stimulus presentations in absence of the shock. Extinction recall and context-induced freezing were measured in subsequent tests. CDPPB, a metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulator, was used to treat these deficits, and region-specific effects were determined using microinjections. RESULTS: These studies determined that CIE exposure led to deficits in fear extinction learning and heightened context-induced freezing while sex differences emerged in fear conditioning and extinction cue recall tests. Furthermore, using CDPPB, these studies found that enhancement of infralimbic (IfL) mGlu5 activity was able to recover CIE-induced deficits in both males and females. CONCLUSIONS: These studies show that CIE induces deficits in fear-related behaviors and that enhancement of IfL glutamatergic activity can facilitate learning during extinction. Additionally, we identify novel pharmacological targets for the treatment of individuals who suffer from PTSD and AUD.
Authors: Richard M Cleva; Megan P Hicks; Justin T Gass; Kelly C Wischerath; Elizabeth T Plasters; John J Widholm; M Foster Olive Journal: Behav Neurosci Date: 2011-02 Impact factor: 1.912
Authors: Mohamed A Zeidan; Sarah A Igoe; Clas Linnman; Antonia Vitalo; John B Levine; Anne Klibanski; Jill M Goldstein; Mohammed R Milad Journal: Biol Psychiatry Date: 2011-07-18 Impact factor: 13.382
Authors: Heather Trantham-Davidson; Samuel W Centanni; S Corrin Garr; Natasha N New; Patrick J Mulholland; Justin T Gass; Elizabeth J Glover; Stan B Floresco; Fulton T Crews; Harish R Krishnan; Subhash C Pandey; L Judson Chandler Journal: Neuropsychopharmacology Date: 2016-09-13 Impact factor: 7.853
Authors: K Lawson; M J Scarlata; W C Cho; C Mangan; D Petersen; H M Thompson; S Ehnstrom; A L Mousley; J L Bezek; H C Bergstrom Journal: Neuropharmacology Date: 2022-03-30 Impact factor: 5.273